DelveInsight's CD47 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, ...

Current health news highlights WeightWatchers offering a compound version of Novo Nordisk's obesity drug, Danco seeking FDA ...

Faced with a moribund share sale outlook and emboldened by their growing recognition on the global stage, some Chinese ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving ...

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and ...

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

Although not all bats carry rabies, the city's health department wants people to seek post-exposure prophylaxis if they were bitten, scratched, or had contact with a bat. Meanwhile, travelers from ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...

In the current market environment, investors might be more interested in generating income rather than capital gains. Today, ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...